Video

Dr. Kumar on Integrating CAR T-Cell Therapy Into Heavily Pretreated Multiple Myeloma

Shaji K. Kumar, MD, discusses the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Shaji K. Kumar, MD, a consultant in the Division of Hematology and a professor of medicine with Mayo Clinic, discusses the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

    On March 26, 2021, the FDA approved idecabtagene vicleucel (ide-cel; Abecma) as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma who progressed on 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and a CD38-directed monoclonal antibody.

    For now, ide-cel will likely be reserved as an option for patients with triple-class refractory disease, says Kumar. As such, ide-cel is competing against other FDA-approved agents, such as belantamab mafodotin-blmf (Blenrep), selinexor (Xpovio), and melphalan flufenamide (melflufen; Pepaxto), Kumar explains.

    Notably, if given the option, many providers would select CAR T-cell therapy over belantamab mafodotin, selinexor, or melflufen because ide-cel demonstrated a high rate of durable responses in patients with heavily pretreated multiple myeloma, Kumar says. However, like the lymphoma paradigm, the reimbursement protocol for ide-cel will not be fully realized for 1 to 3 more years, which limits the treatment’s utility, concludes Kumar.

    Newsletter

    Stay up to date on the most recent and practice-changing oncology data